Half Year Results
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The company reported a notable increase in revenue and a positive operating cash flow, alongside advancements in its clinical trial services and software-as-a-medical-device offerings. Resonance Health's CEO emphasized the strong execution across its business units and the ongoing expansion of its operations. The filing includes an operational update and outlook for the second half of the fiscal year, maintaining previous revenue and EBITDA guidance.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Resonance Health
- Half Year Report & Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- AGM Presentation
- Investor Strategy Day Presentation
- FY25 Full Year Results & FY26 Guidance Investor Presentation
Later from Resonance Health
- Half Year Results Presentation
- Receipt of R&D Tax Incentive Refund
- Profit Guidance Upgrade
- Liver Fibrosis Device Progress & FY26 Portfolio Webinar
- Cessation of Quarterly Reporting
Follow Resonance Health into a list and get an email when it puts out news.
Follow Resonance Health